Phenotypes Associated with This Genotype

Genotype
MGI:3850440

• Allelic Composition: Cdkn2a^tm2Brn/Cdkn2a^tm2Brn; Nf2^tm2Gth/Nf2^tm2Gth
• Genetic Background: involves: 129P2/OlaHsd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:132943 )

• following adenoviral cre treatment, median survival time is 220 days

neoplasm

increased tumor incidence ( J:132943 )

• following adenoviral cre treatment, 83% of mice develop highly invasive thoracic tumors (including malignant mesotheliomas, 45 of 57; rhabdomyosarcomas, 3 of 57; and schwannomas, 1 of 57)

• following adenoviral cre treatment, mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

• following adenoviral cre treatment, 4% of mice develop aspecific tumors not induced by adeno-cre treatment

• following adenoviral cre treatment, 70% of mice develop aggressive malignant mesotheliomas, which is higher than in mice carrying other combinations of Cdkn2a^tm2Brn, Nf2^tm2Gth, and Trp53^tm1Brn alleles

increased uterus leiomyoma incidence ( J:132943 )

♀ • in 4% of mice following adenoviral cre treatment

increased rhabdomyosarcoma incidence ( J:132943 )

increased leukemia incidence ( J:132943 )

• following adenoviral cre treatment, 7% mice develop monocytic myeloid leukemias

liver/biliary system

enlarged liver ( J:132943 )

• following adenoviral cre treatment, 42% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

reproductive system

increased uterus leiomyoma incidence ( J:132943 )

♀ • in 4% of mice following adenoviral cre treatment

muscle

increased uterus leiomyoma incidence ( J:132943 )

♀ • in 4% of mice following adenoviral cre treatment

increased rhabdomyosarcoma incidence ( J:132943 )

growth/size/body

enlarged liver ( J:132943 )

• following adenoviral cre treatment, 42% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
malignant mesothelioma		DOID:1790	OMIM:156240	J:132943